Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder

H. Hermesh*, D. Aizenberg, H. Munitz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Trazodone (TZ) was administered to nine patients suffering from obsessive-compulsive disorder (OCD), who failed to respond to either clomipramine (CMI) or to CMI plus lithium carbonate. The group, as a whole, showed significant but mild improvement. Three patients responded very favorably to TZ. In these three responders, efficacy was substantiated by the return of original obsessive-compulsive (OC) symptoms following TZ withdrawal and their amelioration after its readministration. Interestingly, the aggravation of OCD symptomatology that has been associated with a specific TZ metabolite was not observed. This study is consistent with previous reports of the anti-OC efficacy of TZ and suggests the involvement of complex serotonergic mechanisms in the pathophysiology of this disorder.

Original languageEnglish
Pages (from-to)322-328
Number of pages7
JournalClinical Neuropharmacology
Volume13
Issue number4
DOIs
StatePublished - 1990
Externally publishedYes

Keywords

  • Clomipramine
  • Lithium carbonate
  • Obsessive-compulsive disorder
  • Serotonin
  • Trazodone

Fingerprint

Dive into the research topics of 'Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder'. Together they form a unique fingerprint.

Cite this